Login to Your Account



BioCryst Gets Flu Drug Back On Track, Resumes Enrollment

By Kim Coghill


Friday, January 4, 2002
BioCryst Pharmaceuticals Inc. started out the flu season earlier this week by commencing Phase III enrollment in the United States for its flu treatment, peramivir, after getting clearance from the FDA to resume the study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription